dc.contributor.author | Pasternak, Björn | |
dc.contributor.author | Wintzell, Viktor | |
dc.contributor.author | Mellbye, Mads | |
dc.contributor.author | Eliasson, Björn | |
dc.contributor.author | Svensson, Ann-Marie | |
dc.contributor.author | Franzén, Stefan | |
dc.contributor.author | Gudbjörnsdóttir, Soffia | |
dc.contributor.author | Hveem, Kristian | |
dc.contributor.author | Jonasson, Christian | |
dc.contributor.author | Svanström, Henrik | |
dc.contributor.author | Ueda, Peter | |
dc.date.accessioned | 2021-02-15T08:13:39Z | |
dc.date.available | 2021-02-15T08:13:39Z | |
dc.date.created | 2020-06-09T14:51:47Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | BMJ (Clinical Research Edition). 2020, 369 . | en_US |
dc.identifier.issn | 0959-8138 | |
dc.identifier.uri | https://hdl.handle.net/11250/2727946 | |
dc.description.abstract | OBJECTIVE To assess the association between use of sodiumglucose co-transporter 2 (SGLT2) inhibitors and risk of serious renal events in data from routine clinical practice. DESIGN Cohort study using an active comparator, new user design and nationwide register data. SETTING Sweden, Denmark, and Norway, 2013-18. PARTICIPANTS Cohort of 29 887 new users of SGLT2 inhibitors (follow-up time: dapagliflozin 66.1%; empagliflozin 32.6%; canagliflozin 1.3%) and 29 887 new users of an active comparator, dipeptidyl peptidase-4 inhibitors, matched 1:1 on the basis of a propensity score with 57 variables. Mean follow-up time was 1.7 (SD 1.0) years. EXPOSURES SGLT2 inhibitors versus dipeptidyl peptidase-4 inhibitors, defined by filled prescriptions and analysed according to intention to treat. MAIN OUTCOME MEASURES The main outcome was serious renal events, a composite including renal replacement therapy, death from renal causes, and hospital admission for renal events. Secondary outcomes were the individual components of the main outcome. RESULTS The mean age of the study population was 61.3 (SD 10.5) years; 11 108 (19%) had cardiovascular disease, and 1974 (3%) had chronic kidney disease. Use of SGLT2 inhibitors, compared with dipeptidyl | en_US |
dc.language.iso | eng | en_US |
dc.publisher | BMJ | en_US |
dc.rights | Navngivelse-Ikkekommersiell 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/deed.no | * |
dc.title | Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study | en_US |
dc.type | Peer reviewed | en_US |
dc.type | Journal article | en_US |
dc.description.version | publishedVersion | en_US |
dc.source.pagenumber | 9 | en_US |
dc.source.volume | 369 | en_US |
dc.source.journal | BMJ (Clinical Research Edition) | en_US |
dc.identifier.doi | 10.1136/bmj.m1186 | |
dc.identifier.cristin | 1814595 | |
dc.relation.project | Stiftelsen Kristian Gerhard Jebsen: SKGJ-MED-015 | en_US |
dc.relation.project | Norges forskningsråd: 248817 | en_US |
dc.description.localcode | Denne artikkelen er Open Access, publisert under vilkårene for en Creative Commons-lisens. Se tilbake til artikkelen for å sjekke gjeldende lisens (detaljer er i artikkelen Fotnoter). Artikler publisert under CC-BY-NC tillater ikke-kommersiell bruk, distribusjon og reproduksjon i hvilket som helst medium, forutsatt at det originale arbeidet er sitert riktig. Tillatelse trenger bare å oppnås for kommersiell bruk og kan gjøres via RightsLink-systemet nedenfor. Artikler publisert under CC-BY tillater ubegrenset bruk, distribusjon og reproduksjon i hvilket som helst medium, forutsatt at det opprinnelige verket er riktig sitert. | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |